Skip to main content
Premium Trial:

Request an Annual Quote

Orchid Posts Flat Q2 Revenues, Narrowed Loss

NEW YORK, Aug, 7 (GenomeWeb News) - Orchid Biosciences to reported flat revenue in the second quarter amid decreased R&D spending and narrowed net loss.


Total revenue for the period ended June 30 was $12.4 million, unchanged from the year-ago quarter, Orchid said. However, receipts from the company's core business unit of forensic, paternity, and public health DNA testing increased 11 percent year over year.


R&D spending fell to $1 million, from $5 million, and net loss narrowed to $10.2 million, or $.18 per share, from $12.2 million, or $.22 per share, in the second quarter 2002.


Orchid said it had roughly $15.7 million in cash and cash equivalents as of June 30.


Click here for more information.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.